The Phase I/II trial is being conducted at The Institute of Cancer Research in London and managed by the Drug Development Office of Cancer Research UK, which is funding the trial.
The Phase I/II clinical trial, which is open only to UK women, is an open label, dose escalating study to evaluate the safety and efficacy of CB7630 administered daily to patients with estrogen receptor positive or androgen receptor positive, metastatic breast cancer. Patients enrolled in the trial have disease that has progressed after at least two lines of hormonal therapies, such as aromatase inhibitors and tamoxifen.
Arturo Molina, Cougar’s chief medical officer and executive vice president of clinical R&D, said: “Our clinical trials of CB7630 in advanced prostate cancer patients to date have demonstrated that treatment with CB7630 results in a strong reduction in many of the androgens in the endocrinological pathway, and we believe these androgens may also be driving breast cancer progression. We look forward to future advancement of the clinical development of CB7630 in breast cancer.”